<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial systemic therapy for metastatic urothelial carcinoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial systemic therapy for metastatic urothelial carcinoma</h1>
<div class="graphic"><div class="figure"><div class="ttl">Initial systemic therapy for metastatic urothelial carcinoma</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Patients with advanced or metastatic urothelial carcinoma of the bladder and urinary tract who are not candidates for surgery or radiation therapy may be eligible for initial treatment with systemic agents. Goals of treatment are palliative, and supportive care should be offered. Enrollment in clinical trials is encouraged, where available. Listed treatments are preferred options, although alternative agents that are not listed may also be effective. For further details, refer to UpToDate content on treatment of metastatic urothelial carcinoma.</div><div class="graphic_footnotes"><p>ECOG: Eastern Cooperative Oncology Group; MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin;
NYHA: New York Heart Association.</p>
<p>* Creatinine clearance &lt;60 mL/min is not a contraindication to cisplatin chemotherapy if kidney function is due to tumor obstruction and can be reversed.</p>
<p>¶ Enfortumab vedotin is typically administered in combination with pembrolizumab for a median of 7 to 9 cycles, if tolerable, mainly to avoid the risk of cumulative neurotoxicity. Pembrolizumab is then continued as monotherapy for up to 24 months or until disease progression or unacceptable toxicity during that period.</p>
<p>Δ Either option is appropriate, as the optimal sequencing of chemotherapy and immunotherapy (concurrent versus sequential) is not established.</p>
<p>◊ Nivolumab is administered in combination with gemcitabine and cisplatin every 3 weeks for up to 6 cycles. Nivolumab is then continued as monotherapy for up to 24 months or until disease progression or unacceptable toxicity during that period.</p>
<p>§ The choice between available cisplatin-based regimens is individualized based on patient and provider preferences.</p>
<p>¥ For patients without disease progression on platinum-based chemotherapy regimens, we offer maintenance avelumab. Patients without disease progression who are not eligible for maintenance immunotherapy may be observed with best supportive care.</p>
<p>‡ Patients who are candidates for combination therapy may have appropriate performance status but otherwise be ineligible for cisplatin-based combination chemotherapy due to kidney dysfunction, neuropathy, severe hearing loss, or heart failure.</p>
† Patients not eligible for these regimens may be offered single-agent chemotherapy as an alternative. Options include carboplatin, gemcitabine, vinflunine (where available), anthracyclines, taxanes, methotrexate, and ifosfamide.</div><div id="graphicVersion">Graphic 111737 Version 15.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
